- /
- Supported exchanges
- / US
- / BMY.NYSE
Bristol-Myers Squibb Company (BMY NYSE) stock market data APIs
Bristol-Myers Squibb Company Financial Data Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Bristol-Myers Squibb Company (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Bristol-Myers Squibb Company data using free add-ons & libraries
Get Bristol-Myers Squibb Company Fundamental Data
Bristol-Myers Squibb Company Fundamental data includes:
- Net Revenue: 50 033 M
- EBITDA: 18 242 M
- Earnings Per Share: 4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Bristol-Myers Squibb Company Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-10-29
- EPS/Forecast: 1.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bristol-Myers Squibb Company News
New
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
Revolution Medicines RVMD announced that the European Commission (EC) has approved its once-daily oral pill Rasonque (daraxonrasib) for adults with metastatic pancreatic ductal adenocarcinoma (PDAC) w...
How Investors Are Reacting To Bristol Myers Squibb (BMY) R&D Leadership Overhaul
Bristol Myers Squibb announced that Cristian Massacesi will lead a unified, end-to-end research and development organization from January 2027, with current research chief Robert Plenge staying in an ...
2026 NewYorkCISO ORBIE Awards Recognize Greater New York’s Top Security Executives
Inspire Leadership NetworkMeet the 2026 NewYorkCISO ORBIE Award Winners Leading CISOs honored for leadership, enterprise security, and business impact at the NewYorkCISO ORBIE Awards on November 12, ...
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech has multiple catalysts that could generate a rally of 35% for the stock. Continue Reading
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.